Trial Profile
A Phase 2, Multi-center, Single-arm Study of TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Who Received at Least 2 Prior Lines of Treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Felzartamab (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors I-MAB Biopharma
- 30 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Oct 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 17 Oct 2022 Planned primary completion date changed from 31 Jul 2022 to 30 Jun 2023.